Eli Lilly and Company (LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a new maintenance dosing option for its drug Ebglyss, allowing certain patients aged 12 and older with moderate-to-severe atopic dermatitis to receive injections every eight weeks. This new regimen reduces the treatment frequency to as few as six injections per year, compared to the previous monthly schedule. The approval is supported by data from the Phase 3 ADjoin long-term study, which evaluated both four-week and eight-week dosing over a 32-week period, showing no new safety signals or treatment discontinuations. Medical experts emphasize that this extended dosing option offers greater flexibility for patients managing chronic symptoms. Patient advocates also highlight the reduced treatment burden associated with fewer injections. Adrienne Brown, executive vice president of Lilly Immunology, remarked that this approval enhances Ebglyss' long-term durability, providing a more manageable treatment option for patients. Despite the positive news, LLY shares saw a slight decline in trading following the announcement, although retail sentiment remains bullish with significant engagement on platforms like Stocktwits.